Sangiovanni Timothy J.
Known title: SVP, Corporate ControllerCIK: 0001698328
Sangiovanni Timothy J.'s purchase track record
Sangiovanni Timothy J. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/10/2023 | ZVRA | $5K | +33.7% | +27.4% | +15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▼ Sell | Open Market | 3,000 | $28K | 2/3/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 11,666 | — | 1/31/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 6,333 | — | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 1,750 | $15K | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 3,000 | $24K | 2/13/2025 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 11,666 | — | 1/31/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 1,100 | $5K | 3/10/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 100 | $414 | 3/10/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.